Key result
Developing early new-onset diabetes (<10 years from first visit) in hypertensive patients was associated with increased all-cause mortality (HR 1.39; 95% CI 1.2-1.6) compared to non-diabetics.
Why the study?
Does the timing of new-onset diabetes development affect mortality risk in hypertensive patients?
Cohort (n=15,089)
Does the timing of new-onset diabetes development affect mortality risk in hypertensive patients?
Hazard Ratio: 1.39 (95% CI 1.2–1.6)
In hypertensive patients, developing new-onset diabetes within 10 years of presentation is associated with increased mortality, whereas developing it after 10 years is not.
Early new-onset diabetes may identify higher-risk hypertensive patients for closer surveillance; hypothesis-generating for timing-specific interventions.
AIMS: Hypertension and diabetes mellitus (DM) frequently cluster together and synergistically increase cardiovascular risk. Among those who develop DM during treatment for hypertension (new-onset diabetes, NOD), it is unclear whether NOD reflects a separate entity associated with increased risk or merely reflects accelerated presentation of DM. METHODS AND RESULTS: We analysed data on 15 089 hypertensive patients attending the Glasgow Blood Pressure Clinic. The date at first hospital encounter either with diagnosis of diabetes or prescription of anti-hyperglycaemic medication were considered as the onset of diabetes. Cox proportional hazard models (including propensity score matching) were employed to study associations between diabetes status, early and late NOD (diagnosis <10 years or >10 years from first clinic visit) and cause-specific mortality. There were 2516 patients (16.7%) with DM, of whom 1862 (12.3%) had NOD [early NOD = 705 (4.6%); late NOD = 1157 (7.6%)]. The incidence rate of NOD was 8.2 per 1000 person-years. The total time at risk was 239 929 person-years [median survival: 28.1 years (inter-quartile range: 16.2-39.9)]. Compared with non-diabetic individuals, prevalent DM [hazard ratio (HR) = 1.8, 95% confidence interval (CI): 1.4-2.2] and time varying NOD status (HR: 1.09, 95% CI: 1.06-1.17) were associated with increased adjusted all-cause mortality. Early NOD (HR: 1.39, 95% CI: 1.2-1.6) was associated with increased in mortality risk, but not late NOD (HR: 0.92, 95% CI: 0.83-1.01). Results were consistent in the propensity score matched analyses. CONCLUSION: Although 1-in-8 hypertensive patients develop NOD, mortality is increased only in the 1-in-20 who develop early NOD. Further studies are warranted to determine if early identification of such individuals should provide an alert for intensification of therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Lip et al. (2015) conducted a cohort in Hypertension (n=15,089). Early new-onset diabetes vs. Non-diabetic individuals was evaluated on All-cause mortality (HR 1.39, 95% CI 1.2-1.6). Developing early new-onset diabetes (<10 years from first visit) in hypertensive patients was associated with increased all-cause mortality (HR 1.39; 95% CI 1.2-1.6) compared to non-diabetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: